PT  - JOURNAL ARTICLE
AU  - Marks, Michael
AU  - Gwyn, Sarah
AU  - Toloka, Hilary
AU  - Kositz, Christian
AU  - Asugeni, James
AU  - Asugeni, Rowena
AU  - Diau, Jason
AU  - Kaldor, John M
AU  - Romani, Lucia
AU  - Redman-MacLaren, Michelle
AU  - MacLaren, David
AU  - Solomon, Anthony W
AU  - Mabey, David CW
AU  - Steer, Andrew C
AU  - Martin, Diana
TI  - Impact of community treatment with ivermectin for the control of scabies on the prevalence of antibodies to <em>Strongyloides stercoralis</em> in children
AID  - 10.1101/2019.12.18.19015248
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 2019.12.18.19015248
4099  - http://medrxiv.org/content/early/2019/12/19/2019.12.18.19015248.short
4100  - http://medrxiv.org/content/early/2019/12/19/2019.12.18.19015248.full
AB  - Prevalence of antibodies to Strongyloides stercoralis was measured in 0–12-year-olds using a bead-based immunoassay before and after ivermectin mass drug administration (MDA) for scabies in the Solomon Islands. Seroprevalence was 9.3% before and 5.1% after MDA (p = 0.019), demonstrating collateral benefits of scabies MDA in this setting.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02775617Funding StatementThe study was funded by a Wellcome Trust Clinical PhD fellowship to MM (102807). The US CDC paid the laboratory costs. The funders did not have any role in the design, conduct or analysis of the study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available in supplementary material